Paxil CR Labeling Adds Birth Defects Warning Based On U.S., Swedish Data
Executive Summary
FDA deemed a birth defects warning for GlaxoSmithKline's Paxil CR to be warranted after data from a Swedish birth registry supported an analysis of a U.S. managed care claims database, the agency said